{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:27:37Z","timestamp":1770478057596,"version":"3.49.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We conducted a phase 1\/2 trial of high-dose 90Y-ibritumomab tiuxetan in combination with high-dose etoposide (VP-16) 40 to 60 mg\/kg (day -4) and cyclophosphamide 100 mg\/kg (day -2) followed by autologous stem cell transplantation (ASCT) in 31 patients with CD20+ non-Hodgkin lymphoma (NHL). Patients underwent dosimetry (day -21) with 5 mCi (185 MBq) 111In-ibritumomab tiuxetan following 250 mg\/m2 rituximab, followed a week later by 90Y-ibritumomab tiuxetan to deliver a target dose of 1000 cGy to highest normal organ. Bone marrow biopsy was done on day -7 to estimate radiation dose and stem cells were reinfused when the radiation dose was estimated to be less than 5 cGy. The median 90Y-ibritumomab tiuxetan dose was 71.6 mCi (2649.2 MBq; range, 36.6-105 mCi; range, 1354.2-3885 MBq). Histology included follicular lymphoma (n = 12), diffuse large B-cell (n = 14), and mantle cell (n = 5). The median number of prior chemo-therapy treatments was 2. The treatment was well tolerated. The median times to reach an absolute neutrophil count greater than 500\/\u03bcL and platelet count more than 20 000\/\u03bcL were 10 days and 12 days, respectively. There were 2 deaths and 5 relapses. At a median follow-up of 22 months, the 2-year estimated overall survival and relapse-free survival rates are 92% and 78%, respectively. We conclude that high-dose 90Y-ibritumomab tiuxetan can be combined safely with high-dose etoposide and cyclophosphamide without an increase in transplant-related toxicity or delayed engraftment. (Blood. 2005;106:2896-2902)<\/jats:p>","DOI":"10.1182\/blood-2005-03-1310","type":"journal-article","created":{"date-parts":[[2005,7,7]],"date-time":"2005-07-07T20:33:39Z","timestamp":1120768419000},"page":"2896-2902","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":172,"title":["A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma"],"prefix":"10.1182","volume":"106","author":[{"given":"Auayporn","family":"Nademanee","sequence":"first","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Forman","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Molina","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Fung","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Smith","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Dagis","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheuk","family":"Kwok","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Line","family":"Anderson","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Falk","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amrita","family":"Krishnan","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Kirschbaum","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Kogut","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Parker","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Popplewell","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firoozeh","family":"Sahebi","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Smith","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Snyder","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Stein","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Spielberger","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"White","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Raubitschek","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, Division of Information Services, Department of Radioimmunotherapy, and Division of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA; and Biogen Idec, Cambridge, MA\/San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021216294539200_REF1","doi-asserted-by":"crossref","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med.1993;328: 1002-1006.","DOI":"10.1056\/NEJM199304083281404"},{"key":"2020021216294539200_REF2","doi-asserted-by":"crossref","unstructured":"Vose JM, Anderson JR, Kessinger A, et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol.1993;11: 1846-1851.","DOI":"10.1200\/JCO.1993.11.10.1846"},{"key":"2020021216294539200_REF3","doi-asserted-by":"crossref","unstructured":"Nademanee A, Molina A, Dagis A, et al. Autologous stem cell transplantation for poor-risk and relapsed intermediate-and high-grade non-Hodgkin's lymphoma. Clin Lymphoma.2000;1: 46-54.","DOI":"10.3816\/CLM.2000.n.004"},{"key":"2020021216294539200_REF4","doi-asserted-by":"crossref","unstructured":"Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemo-therapy-sensitive non-Hodgkin's lymphoma. N Engl J Med.1995;333: 1540-1545.","DOI":"10.1056\/NEJM199512073332305"},{"key":"2020021216294539200_REF5","doi-asserted-by":"crossref","unstructured":"Horning SJ, Negrin RS, Chao NJ, et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol.1994;12: 2552-2558.","DOI":"10.1200\/JCO.1994.12.12.2552"},{"key":"2020021216294539200_REF6","doi-asserted-by":"crossref","unstructured":"Weaver CH, Petersen FB, Appelbaum FA, et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol.1994;12: 2559-2566.","DOI":"10.1200\/JCO.1994.12.12.2559"},{"key":"2020021216294539200_REF7","doi-asserted-by":"crossref","unstructured":"Stiff PJ, Dahlberg S, Forman SJ, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens\u2014-a Southwest Oncology Group trial. J Clin Oncol.1998;16: 48-55.","DOI":"10.1200\/JCO.1998.16.1.48"},{"key":"2020021216294539200_REF8","unstructured":"Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol.1999;26: 58-65."},{"key":"2020021216294539200_REF9","doi-asserted-by":"crossref","unstructured":"Press OW, Eary JF, Appelbaum FR, et al. Radio-labeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med.1993;329: 1219-1224.","DOI":"10.1056\/NEJM199310213291702"},{"key":"2020021216294539200_REF10","doi-asserted-by":"crossref","unstructured":"Press OW, Eary JF, Gooley T, et al. A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood.2000;96: 2934-2942.","DOI":"10.1182\/blood.V96.9.2934"},{"key":"2020021216294539200_REF11","doi-asserted-by":"crossref","unstructured":"Witzig TE, White CA, Wiseman GA, et al. Phase I\/II trial of IDEC-Y2B8 radioimmnotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol.1999;17: 3793-3803.","DOI":"10.1200\/JCO.1999.17.12.3793"},{"key":"2020021216294539200_REF12","doi-asserted-by":"crossref","unstructured":"Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol.2002;20: 2453-2463.","DOI":"10.1200\/JCO.2002.11.076"},{"key":"2020021216294539200_REF13","doi-asserted-by":"crossref","unstructured":"Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1\/2 study. Blood.2004;103: 4429-4431.","DOI":"10.1182\/blood-2003-11-3883"},{"key":"2020021216294539200_REF14","doi-asserted-by":"crossref","unstructured":"Rastetter W, Molina A, White CA. Expanding role in therapy for lymphomas and autoimmune diseases. Ann Rev Med.2004;55: 503-2004.","DOI":"10.1146\/annurev.med.55.091902.104249"},{"key":"2020021216294539200_REF15","doi-asserted-by":"crossref","unstructured":"Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol.2005;23: 461-467.","DOI":"10.1200\/JCO.2005.05.117"},{"key":"2020021216294539200_REF16","unstructured":"Winter JN, Inwards D, Erwin W, et al. Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: early outcome results [abstract]. Blood.2002;100: 411a."},{"key":"2020021216294539200_REF17","unstructured":"Fung HC, Forman SJ, Nademanee A, et al. A new preparative regimen for older patients with aggressive CD 20 positive B-cell lymphoma utilizing standard dose yttrium-90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM followed by autologous hematopoietic cell transplantation (AHCT): targeted intensification without increased transplant-related toxicity [abstract]. Blood.2003;102: 248a."},{"key":"2020021216294539200_REF18","doi-asserted-by":"crossref","unstructured":"Bierman PJ, Vose JM, Anderson JR, et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol.1997;15: 445-450.","DOI":"10.1200\/JCO.1997.15.2.445"},{"key":"2020021216294539200_REF19","doi-asserted-by":"crossref","unstructured":"Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood.1999;94: 3325-3333.","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333"},{"key":"2020021216294539200_REF20","doi-asserted-by":"crossref","unstructured":"Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed\/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol.2000;18: 1316-1323.","DOI":"10.1200\/JCO.2000.18.6.1316"},{"key":"2020021216294539200_REF21","doi-asserted-by":"crossref","unstructured":"Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol.2003;21: 1263-1270.","DOI":"10.1200\/JCO.2003.08.043"},{"key":"2020021216294539200_REF22","doi-asserted-by":"crossref","unstructured":"Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood.2003;102: 2351-2357.","DOI":"10.1182\/blood-2003-02-0622"},{"key":"2020021216294539200_REF23","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol.1998;16: 1922-1930.","DOI":"10.1200\/JCO.1998.16.5.1922"},{"key":"2020021216294539200_REF24","doi-asserted-by":"crossref","unstructured":"Fisher RI, Dahlberg S, Nathwani BN, et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood.1995;85: 1075-1082.","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"2020021216294539200_REF25","doi-asserted-by":"crossref","unstructured":"Vose JM, Bierman PJ, Weisenburger DD, et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant.2000;6: 640-645.","DOI":"10.1016\/S1083-8791(00)70030-9"},{"key":"2020021216294539200_REF26","doi-asserted-by":"crossref","unstructured":"Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol.1998;16: 13-18.","DOI":"10.1200\/JCO.1998.16.1.13"},{"key":"2020021216294539200_REF27","unstructured":"Molina A, Kraft D, Carter N, et al. Autologous stem cell transplantation (ASCT) for mantle cell lymphoma (MCL): a report of 69 patients from City of Hope (COH) and Stanford [abstract]. Blood.2002;100(suppl 1): 182a."},{"key":"2020021216294539200_REF28","doi-asserted-by":"crossref","unstructured":"Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood.2002;99: 3158-3162.","DOI":"10.1182\/blood.V99.9.3158"},{"key":"2020021216294539200_REF29","doi-asserted-by":"crossref","unstructured":"Behr TM, Griesinger F, Riggert J, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support: results of a pilot study. Cancer.2002;94: 1363-1372.","DOI":"10.1002\/cncr.10307"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/8\/2896\/1635739\/zh802005002896.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/8\/2896\/1635739\/zh802005002896.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T16:30:00Z","timestamp":1581525000000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/8\/2896\/21826\/A-phase-12-trial-of-highdose-yttrium90ibritumomab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,15]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-03-1310","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,15]]}}}